Proactive Investors - Run By Investors For Investors

BARD1 Life Sciences shares surge after positive ovarian cancer test

The BARD1 ovarian cancer test is an ELISA-based blood test.
BARD1 Life Sciences shares surge after positive ovarian cancer test
The test detected all stages of ovarian cancer

BARD1 Life Sciences (ASX:BD1) shares were trading 110% higher intra-day after successfully completing a clinical trial of its proprietary ovarian cancer diagnostic test.

The trial involving 348 samples (200 women with ovarian cancer and 148 controls) found the test to have both high specificity (87%) and high sensitivity (90%).

In addition, the test detected all subtypes and stages of ovarian cancer in the samples with the performance of the test between early-stage and late stage ovarian cancer not statistically different.

The BARD1 Ovarian Cancer Test is an ELISA-based blood test that uses a panel of peptides on a solid surface.

When exposed to a blood sample, the test measures the binding of antibodies in the patient’s blood to these peptides.

Previous data from smaller scale studies had already established the proof of concept of the test and initial indications of high sensitivity and specificity.

With high levels of accuracy shown to all stages of ovarian cancer, the BARD1 test may offer a substantial improvement over existing ovarian cancer blood tests.

The test is expected to improve the accurate detection of cancer at all stages with few false positives.

Further studies are planned to demonstrate the use of the BARD1 Ovarian Cancer Test for distinction of benign ovarian lesions and cancer.

The company is also focused on its lead product, the BARD1 Lung Cancer Test, for early detection of lung cancer utilising novel tumour markers and a proprietary algorithm.

BARD1’s closing cash balance as at 31 December 2016 was circa $1.93 million.

View full BD1 profile View Profile

Bard1 Life Sciences Ltd Timeline

Related Articles

copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
seeds in a bowl
March 08 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives
1550850611_CancerHeadline.jpg
February 23 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use